Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and
COVID-19

Parakriti      Gupta; Diljot      Sandhu; Varsha      Gupta; Lipika      Singhal

doi:10.2174/0118715265259959231031104820

Abstract

The Coronavirus-19 (COVID-19) hasn’t seen the dawn since its emergence, however waxing and waning has resulted in the emergence of deadly variants. The effects of pandemic have not been limited to its virulence, but have rather conferred multiple collateral effects, especially in developing countries; thereby, designating it as a SYNDEMIC. The same culminated in neglect of non-COVID-19 conditions like tuberculosis (TB) and human immunodeficiency virus-acquired immunodeficiency syndrome (HIV/AIDS). Besides being the prognostic factor for severe COVID-19, these infections in hidden pockets served as reservoir for emergence of the deadly Omicron. Another significant impact of this juxtaposition was on the delivery of healthcare services for TB and HIV.

The unanticipated COVID-19 pandemic turned the path of ongoing progress of elimination programs. Direct consequences of the COVID-19 pandemic were pronounced on diagnosis, treatment, and services for patients with TB and HIV. Essential TB services were reallocated to the COVID-19 rapid response task force. However, despite escalating the tribulations, this triple burden has simultaneously taught lessons to escalate the progress of halted programs. The pandemic has catalyzed an unusual level of collaboration among scientists, which can be exploited for TB and HIV. Fast-track diagnostics, digitalization, contact tracing, and vaccine development have enabled world to envision the same for TB/HIV.

Graphical Abstract

[1]
 WHO Statement Regarding Cluster of Pneumonia Cases in Wuhan, China. Available from:
          https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china

[2]
Tracking SARS-CoV-2 variants. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants

[3]
Courtin E, Vineis P. COVID-19 as a syndemic. Front Public Health  2021; 9763830.
 [http://dx.doi.org/10.3389/fpubh.2021.763830] [PMID: 34568273]

[4]
Piketty J, Carbonnel M, Murtada R, et al. Collateral damage of COVID-19 pandemic: The impact on a gynecologic surgery department. J Gynecol Obstet Hum Reprod  2022; 51(1): 102255.
 [http://dx.doi.org/10.1016/j.jogoh.2021.102255] [PMID: 34757223]

[5]
Thiagarajan K. Covid-19 exposes the high cost of India’s reliance on private healthcare. BMJ  2020; 370: m3506.
 [http://dx.doi.org/10.1136/bmj.m3506] [PMID: 32912849]

[6]
Tamuzi JL, Ayele BT, Shumba CS, et al. Implications of COVID-19 in high burden countries for HIV/TB: A systematic review of evidence. BMC Infect Dis  2020; 20(1): 744.
 [http://dx.doi.org/10.1186/s12879-020-05450-4] [PMID: 33036570]

[7]
The Connection between TB and HIV | Pamphlets, Brochures, Booklets|Publications & Products | TB | CDC. 2022. Available from: https://www.cdc.gov/tb/publications/pamphlets/tbandhiv_eng.htm

[8]
Waters R, Ndengane M, Abrahams MR, Diedrich CR, Wilkinson RJ, Coussens AK. The Mtb -HIV syndemic interaction: Why treating M. tuberculosis infection may be crucial for HIV-1 eradication. Future Virol  2020; 15(2): 101-26.
 [http://dx.doi.org/10.2217/fvl-2019-0069] [PMID: 32273900]

[9]
Ssentongo P, Ssentongo AE, Heilbrunn ES, Du P. 393. Prevalence of HIV in patients hospitalized for COVID-19 and associated mortality outcomes: A systematic review and meta-analysis. Open Forum Infect Dis  2020; 7(S1): S266.
 [http://dx.doi.org/10.1093/ofid/ofaa439.588]

[10]
Nachega JB, Kapata N, Sam-Agudu NA, et al. Minimizing the impact of the triple burden of COVID-19, tuberculosis and HIV on health services in sub-Saharan Africa. Int J Infect Dis  2021; 113(S1): S16-21.
 [http://dx.doi.org/10.1016/j.ijid.2021.03.038] [PMID: 33757874]

[11]
Karim SSA, Churchyard GJ, Karim QA, Lawn SD. HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet  2009; 374(9693): 921-33.
 [http://dx.doi.org/10.1016/S0140-6736(09)60916-8] [PMID: 19709731]

[12]
Khandia R, Singhal S, Alqahtani T, et al. Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res  2022; 209112816.
 [http://dx.doi.org/10.1016/j.envres.2022.112816] [PMID: 35093310]

[13]
Freer J, Mudaly V. HIV and covid-19 in South Africa BMJ 2022; 376e069807 
 [http://dx.doi.org/10.1136/bmj-2021-069807] [PMID: 35086921]

[14]
Brumme ZL, Mwimanzi F, Lapointe HR, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. medRxiv  2021; 2021.10.03.21264320.
 [http://dx.doi.org/10.1101/2021.10.03.21264320]

[15]
Coronavirus disease (COVID-19) and people living with HIV. Available
	from:. https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-covid-19-and-people-living-with-hiv

[16]
Logunov DY, Livermore DM, Ornelles DA, et al. COVID-19 vaccination and HIV-1 acquisition. Lancet  2022; 399(10333): e34-5.
 [http://dx.doi.org/10.1016/S0140-6736(22)00332-4] [PMID: 35397866]

[17]
Chun HM, Milligan K, Agyemang E, et al. A systematic review of COVID-19 vaccine antibody responses in people with HIV. Open Forum Infect Dis  2022; 9(11): ofac579.
 [http://dx.doi.org/10.1093/ofid/ofac579] [PMID: 36438620]

[18]
Hassold N, Brichler S, Ouedraogo E, et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection. AIDS  2022; 36(4): F1-5.
 [http://dx.doi.org/10.1097/QAD.0000000000003166] [PMID: 35013085]

[19]
Hogan AB, Jewell BL, Sherrard-Smith E, et al. Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Glob Health  2020; 8(9): e1132-41.
 [http://dx.doi.org/10.1016/S2214-109X(20)30288-6] [PMID: 32673577]

[20]
Global Fund Results Report Reveals COVID-19 Devastating Impact
	on HIV, TB and Malaria Programs. Available from: https://www.theglobalfund.org/en/news/2021/2021-09-08-global-fund-results-report-reveals-covid-19-devastating-impact-on-hiv-tb-and-malaria-programs/

[21]
Can Sarınoğllu R, Sili U, Eryuksel E, Olgun Yildizeli S, Cimsit C, Karahasan Yagci A. Tuberculosis and COVID-19: An overlapping situation during pandemic. J Infect Dev Ctries  2020; 14(7): 721-5.
 [http://dx.doi.org/10.3855/jidc.13152] [PMID: 32794460]

[22]
Tuberculosis deaths rise for the first time in more than a decade due to the COVID-19 pandemic. Available from: https://www.who.int/news/item/14-10-2021-tuberculosis-deaths-rise-for-the-first-time-in-more-than-a-decade-due-to-the-covid-19-pandemic

[23]
 On World TB day WHO calls for increased investments into TB services and research. Available from: https://www.who.int/news/item/21-03-2022-on-world-tb-day-who-calls-for-increased-investments-into-tb-services-and-research

[24]
Perween R. PraveenKumar M, Shrivastava T, et al. The SARS CoV-2 spike directed non-neutralizing polyclonal antibodies cross-react with Human immunodeficiency virus (HIV-1) gp41. Int Immunopharmacol 2021; 101(Pt B): 108187.
 [http://dx.doi.org/10.1016/j.intimp.2021.108187] [PMID: 34649114]

[25]
Silver ZA, Antonopoulos A, Haslam SM, et al. Discovery of o-linked carbohydrate on HIV-1 envelope and its role in shielding against one category of broadly neutralizing antibodies. Cell Rep  2020; 30(6): 1862-1869.e4.
 [http://dx.doi.org/10.1016/j.celrep.2020.01.056] [PMID: 32049016]

[26]
Mishra N, Kumar S, Singh S, et al. Cross-neutralization of SARS-CoV-2 by HIV-1 specific broadly neutralizing antibodies and polyclonal plasma. PLoS Pathog  2021; 17(9): e1009958.
 [http://dx.doi.org/10.1371/journal.ppat.1009958] [PMID: 34559854]

[27]
Global tuberculosis report 2020. Available from:. https://www.who.int/publications-detail-redirect/9789240013131

[28]
CDC announces Think. Test. Treat TB: a campaign to raise awareness
	of latent TB infection | Dear Colleague Letters | TB | CDC.
	Available from: https://www.cdc.gov/tb/publications/letters/2022/tb-campaign.html

[29]
TB & COVID-19. Available from:. https://www.who.int/teams/global-tuberculosis-programme/covid-19

[30]
Mousquer GT, Peres A, Fiegenbaum M. Pathology of TB/COVID-19 Co-Infection: The phantom menace. Tuberculosis  2021; 126102020.
 [http://dx.doi.org/10.1016/j.tube.2020.102020] [PMID: 33246269]

[31]
The End TB Strategy. Available from:. https://www.who.int/teams/global-tuberculosis-programme/the-end-tb-strategy

[32]
States and UTs accelerate action to end TB by 2025. Available from:. https://www.who.int/india/news/detail/09-11-2021-states-and-uts-accelerate-action-to-end-tb-by-2025

[33]
Cilloni L, Fu H, Vesga JF, et al. The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis. EClinicalMedicine  2020; 28100603.
 [http://dx.doi.org/10.1016/j.eclinm.2020.100603] [PMID: 33134905]

[34]
WHO Global TB progress at risk Available from: https://www.who.int/news/item/14-10-2020-who-global-tb-progress-at-risk

[35]
End TB. The clock is ticking | World Economic Forum. Available from:. https://www.weforum.org/agenda/2021/03/end-tb-the-clock-is-ticking/

[36]
Shrinivasan R, Rane S, Pai M. India’s syndemic of tuberculosis and COVID-19. BMJ Glob Health  2020; 5(11): e003979.
 [http://dx.doi.org/10.1136/bmjgh-2020-003979] [PMID: 33199280]

[37]
Tuberculosis and COVID-19 | Stop TB Partnership. Available from: . https://www.stoptb.org/covid19

[38]
The impact of COVID-19 on HIV, TB and malaria services and systems
	for health - Updates - The Global Fund to Fight AIDS, Tuberculosis
and Malaria. Available from: https://www.theglobalfund.org/en/updates/2021/2021-04-13-the-impact-of-covid-19-on-hiv-tb-and-malaria-services-and-systems-for-health/

[39]
HMIS-Health Management Information System. Available from:. https://hmis.nhp.gov.in/#!/aboutus

[40]
Chatterjee P. Is India missing COVID-19 deaths? Lancet  2020; 396(10252): 657.
 [http://dx.doi.org/10.1016/S0140-6736(20)31857-2] [PMID: 32891197]

[41]
Unite To Fight. Available from:. https://www.theglobalfund.org/en/unite-to-fight/

[42]
Directives regarding TB services during Covid19 emergency period ::	Central TB Division. Available from: https://tbcindia.gov.in/index1.php?lang=1&level=1&sublinkid=5428&lid=3509

[43]
Pai M. Tuberculosis And Covid-19: Fighting A Deadly Syndemic.
	Forbes. Available from: https://www.forbes.com/sites/madhukarpai/2020/09/26/tuberculosis-and-covid-19-fighting-a-deadly-syndemic/

[44]
How Covid is making it tougher to tackle TB, AIDS, malaria and
	child health. Available from: https://theprint.in/health/how-covid-is-making-it-tougher-to-tackle-tb-aids-malaria-and-child-health/443658/

[45]
Technical guidance. Available from: https://www.who.int/india/home/emergencies/ongoing-disease-outbreak-disasters/technical-guidance

[46]
Coronavirus disease (COVID-19): HIV and antiretrovirals. Available
	from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-hiv-and-antiretrovirals

[47]
An S, Li Y, Lin Y, et al. Genome-wide profiling reveals alternative polyadenylation of innate immune-related mRNA in patients with COVID-19. Front Immunol  2021; 12756288.
 [http://dx.doi.org/10.3389/fimmu.2021.756288] [PMID: 34777369]

[48]
Chen Y, Wang G, Li J, et al. CASA: A comprehensive database resource for the COVID-19 Alternative splicing atlas. J Transl Med  2022; 20(1): 473.
 [http://dx.doi.org/10.1186/s12967-022-03699-8] [PMID: 36266726]

[49]
An S, Xie Z, Liao Y, et al. Systematic analysis of clinical relevance and molecular characterization of m6A in COVID-19 patients. Genes Dis  2022; 9(5): 1170-3.
 [http://dx.doi.org/10.1016/j.gendis.2021.12.005] [PMID: 35013711]

[50]
Joy M, Malavika B, Asirvatham ES, Sudarsanam TD, Jeyaseelan L. Is BCG associated with reduced incidence of COVID-19? A meta-regression of global data from 160 countries. Clin Epidemiol Glob Health  2021; 9: 202-3.
 [http://dx.doi.org/10.1016/j.cegh.2020.08.015] [PMID: 33163696]

[51]
Gong W, Mao Y, Li Y, Qi Y. BCG vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents. Int Immunopharmacol  2022; 108108870.
 [http://dx.doi.org/10.1016/j.intimp.2022.108870] [PMID: 35597119]

[52]
Glynn JR, Dube A, Fielding K, Crampin AC, Kanjala C, Fine PEM. The effect of BCG revaccination on all-cause mortality beyond infancy:
30-year follow-up of a population-based, double-blind, randomised
placebo-controlled trial in Malawi. Lancet Infect Dis 2021; (21)11: 1590-7.
 [http://dx.doi.org/10.1016/S1473-3099(20)30994-4] [PMID: 34237262]

[53]
COVID-19 Strategic Preparedness and Response Plan Operational
Planning Guideline. Available from: https://www.who.int/publications/m/item/covid-19-strategicpreparedness-and-response-plan-operational-planning-guideline

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715265259959231031104820	Print ISSN 1871-5265
Publisher Name Bentham Science Publisher	Online ISSN 2212-3989

Infectious Disorders - Drug Targets

Triple Burden: The Incorrigible Threat of Tuberculosis, HIV, and COVID-19

Abstract Play Pause

Graphical Abstract

Related Journals

Related Books

Abstract